These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9586268)

  • 1. [Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder].
    Arango Toro O; Nohales Taurines G; Cortadellas Angel R; Castro Santamaría R; Gelabert Mas A
    Actas Urol Esp; 1998 Feb; 22(2):124-30. PubMed ID: 9586268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P; Borkowski A
    Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women].
    Serrano Brambila EA; Quiroga Avila RG; Lorenzo Monterrubio JL; Moreno Aranda J
    Ginecol Obstet Mex; 2000 Apr; 68():174-81. PubMed ID: 10824450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
    Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
    Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.
    Corcos J; Casey R; Patrick A; Andreou C; Miceli PC; Reiz JL; Harsanyi Z; Darke AC;
    BJU Int; 2006 Mar; 97(3):520-7. PubMed ID: 16469019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal oxybutynin (oxytrol) for urinary incontinence.
    Dull P
    Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
    Wang AC; Chih SY; Chen MC
    Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
    Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
    Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of oxybutynin treatment on cognition in children with diurnal incontinence.
    Sommer BR; O'Hara R; Askari N; Kraemer HC; Kennedy WA
    J Urol; 2005 Jun; 173(6):2125-7. PubMed ID: 15879864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.
    Versi E; Appell R; Mobley D; Patton W; Saltzstein D
    Obstet Gynecol; 2000 May; 95(5):718-21. PubMed ID: 10775736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
    Palmer LS; Zebold K; Firlit CF; Kaplan WE
    J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V;
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.